-Angel Yeast Partners with PhaBuilder to Drive Broader Synthetic Biology Applications with Launch of PHA Manufacturing Joint Venture
YICHANG, China, June 29, 2023 /PRNewswire/ -- Angel Yeast (SHA:600298), the world's leading yeast manufacturer, together with Beijing PhaBuilder in a joint venture, Hubei PHAngel Biotechnology, recently put under construction a large polyhydroxyalkanoate (PHA) production line in Hubei province. In early June, the two partners held a launch ceremony to mark the event and the opening of Hubei's first synthetic biology (SynBio) industrial park. Academicians from the Chinese Academy of Sciences, government officials, executives from Angel Yeast, PhaBuilder and Siemens China attended.
The PHA factory, located in Yichang City, has a production line capacity of 30,000 tons and is the largest PHA production line built using Next Generation Industrial Biotechnology (NGIB) in the world. PHAs are a polyester naturally produced by microorganisms and its biodegradable and biocompatible properties make it highly sought after in fields such as biomedical material and biodegradable packaging material. Already a trending field in biotechnology, the SynBio sector has grown rapidly supported by advanced technologies and a growing demand for SynBio applications.
Zhang Xu, Deputy Director of Angel Yeast's Investment and Strategy Department, said, "We have intensified our efforts in synthetic biology and its applications, and the opening of the PHA factory is an important milestone and a significant step forward for Angel Yeast at SynBio. It aligns with our commitment to sustainability and will drive green and low-carbon development in manufacturing."
In addition to the PHA factory, Angel Yeast has released a strategic plan for SynBio. Their goal is to build a comprehensive service platform that meets the needs of biotech companies when processing and commercializing SynBio products. The Company will also seize subsequent opportunities and actively seek cooperation partners who have complementary advantages in technology, products, channels and brand. It will promote the application of SynBio in areas such as healthcare, biodiversity preservation and pharmaceuticals.
According to data from CB Insights, the size of the global synthetic biology market is projected to reach $18.9 billion by 2024. In China, as noted by Deng Zixin, an academic at the Chinese Academy of Sciences and a professor at Jiao Tong University From Shanghai, SynBio technologies are rapidly progressing towards practical and industrial applications, so it is vitally important that various sectors and industries collaborate to push their development to new heights.
Photo - https://mma.prnewswire.com/media/2140367...Logo - https://mma.prnewswire.com/media/1586948...
View original content: https://www.prnewswire.com/news-releases/angel-yeast-se-asocia-con-phabuilder-y-lanzan-la-empresa-conjunta-de-fabricacion-de-pha-301863320.html